Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in colorectal cancer is the V600E mutation, which is present in 5-15% of all tumors, and up to 80% of tumors with high microsatellite instability (MSI) harbor this mutation. BRAF mutation is associated with proximal location, higher age, female gender, MSI-H, high grade, and mucinous histology, and is a marker of poor prognosis in colorectal cancer. The role of BRAF mutation as a predictive marker in respect of EGFR targeted treatments is controversial. BRAF V600 selective inhibitors have been approved for the treatment of V600 mutation positive metastatic melanoma, but the response rates in colorectal cancer are poor. This might be due to innate resistance mechanisms of colorectal cancers against the treatment solely targeting BRAF. To overcome resistance the combination of treatments, simultaneous inhibition of BRAF and MEK or PI3K/mTOR, might emerge as a successful therapeutic concept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 1×
“PREDICTIVE ROLE It has been suggested that in order for metastatic colorectal cancer patients to receive a response for treatment with monoclonal antibodies targeting EGFR (panitumumab and cetuximab, Figure 1C), the BRAF gene needs to be present as wild-type (37, 38).”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 1×
“Similarly, BRAF mutation was not predictive for treatment with cetuximab, but was a marker of poor prognosis in metastatic colorectal cancer patients (KRAS wild-type) that were randomly assigned to treatment with FOLFIRI (irinotecan, fluorouracil, leucovorin) with or without cetuximab in the CRYSTAL study (42).”
MethodTumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 3×
“BRAF V600E mutated colorectal cancer on the contrary, seems to display an innate resistance to inhibition with BRAF inhibitors, which was also demonstrated in colorectal cancer cell lines (55, 58, 59).”
BackgroundWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“PREDICTIVE ROLE It has been suggested that in order for metastatic colorectal cancer patients to receive a response for treatment with monoclonal antibodies targeting EGFR (panitumumab and cetuximab, Figure 1C), the BRAF gene needs to be present as wild-type (37, 38).”
BackgroundCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454 · cited 1×
“ERKdependent resistance mechanisms can occur via activating MEK1 mutations (61), activating NRAS mutations (62), COT overexpression (63), elevated CRAS activity (64), BRAF V600E alternative splicing or amplification (65).”
BackgroundRichman, S. D., Seymour, M. T., Chambers, P., Elliott, F., Daly, C. L., Meade, A. M., Taylor, G., Barrett, J. H., & Quirke, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4295 · Cited by 560
(2019) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1200/jco · Cited by 522
Cited by
Mucinous colorectal adenocarcinoma: clinical pathology and treatment options
Luo, C., Cen, S., Ding, G., & Wu, W. (2019) · Cancer Communications · doi:10.1186/s40880-019-0361-0 · Cited by 313
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11743 · Cited by 207
Koustas, E., Karamouzis, M. V., Mihailidou, C., Schizas, D., & Papavassiliou, A. G. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.023 · Cited by 79
When to screen and not to screen
Cruickshanks, N. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.27741 · Cited by 1
Metadata
- Authors
- Thiel, A., & Ristimäki, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 281-281
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2087847384
- Cited by
- 70
- References
- 16
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. https://app.cochat.ai/papers/10.3389/fonc.2013.00281
- The paper
- Thiel, A., & Ristimäki, A. (2013). Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Frontiers in Oncology. https://doi.org/10.3389/fonc.2013.00281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.